doi: 10.1016/s0959-8049(98)00232-9.
Stage-specific treatment costs for cervical cancer in the United Kingdom
Affiliations
- PMID: 10023311
- DOI: 10.1016/s0959-8049(98)00232-9
Item in Clipboard
Stage-specific treatment costs for cervical cancer in the United Kingdom
Eur J Cancer.
1998 Nov.
Abstract
In order to examine the relationship between stage at initial diagnosis and management costs for cervical cancer, a detailed cost audit over 5 years was conducted on a sample of patients diagnosed in 1990 in one U.K. region. The mean costs of managing pre-invasive carcinoma (386 Pounds) were found to be significantly lower than those of stage 1 invasive carcinoma (6623 Pounds) and both were lower than the costs of invasive cancer at stages 2-4 (10,910 Pounds, 10,579 Pounds and 11,035 Pounds, respectively). A comparison of management costs for cervical cancer with those of breast cancer by stage revealed both that the former are invariably higher and that the cost-by-stage profiles for the two diseases are dissimilar.
Similar articles
-
Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK.Curr Med Res Opin. 2006 Apr;22(4):663-70. doi: 10.1185/030079906X99972. Curr Med Res Opin. 2006. PMID: 16684427
-
Costs of cervical cancer and precancerous lesions treatment in a publicly financed health care system.Arch Gynecol Obstet. 2010 Apr;281(4):683-95. doi: 10.1007/s00404-009-1218-6. Arch Gynecol Obstet. 2010. PMID: 19730873
-
Cost of cervical cancer treatment: implications for providing coverage to low-income women under the Medicaid expansion for cancer care.Womens Health Issues. 2010 Nov-Dec;20(6):400-5. doi: 10.1016/j.whi.2010.07.002. Womens Health Issues. 2010. PMID: 21050999
-
Cervical neoplasia.Clin Obstet Gynecol. 2011 Dec;54(4):528-36. doi: 10.1097/GRF.0b013e318236c606. Clin Obstet Gynecol. 2011. PMID: 22031243 Review.
-
[Treatment of micro-invasive cervical cancers].J Gynecol Obstet Biol Reprod (Paris). 1997;26(3 Suppl):191-4. J Gynecol Obstet Biol Reprod (Paris). 1997. PMID: 9471458 Review. French. No abstract available.
Cited by
-
Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis.Cost Eff Resour Alloc. 2008 Feb 15;6:4. doi: 10.1186/1478-7547-6-4. Cost Eff Resour Alloc. 2008. PMID: 18279515 Free PMC article.
-
Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.PLoS One. 2015 Sep 23;10(9):e0139062. doi: 10.1371/journal.pone.0139062. eCollection 2015. PLoS One. 2015. PMID: 26398189 Free PMC article.
-
Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studies.BMJ. 2006 Jan 14;332(7533):79-85. doi: 10.1136/bmj.38698.458866.7C. Epub 2006 Jan 6. BMJ. 2006. PMID: 16399769 Free PMC article.
-
Economic evaluation of human papilloma virus vaccination in the European Union: a critical review.Intern Emerg Med. 2011 Apr;6(2):163-74. doi: 10.1007/s11739-011-0529-3. Epub 2011 Feb 11. Intern Emerg Med. 2011. PMID: 21312004 Review.
-
The economic burden of cervical cancer in Eswatini: Societal perspective.PLoS One. 2021 Apr 15;16(4):e0250113. doi: 10.1371/journal.pone.0250113. eCollection 2021. PLoS One. 2021. PMID: 33857233 Free PMC article.
